View Post

Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with standard-of-care ado-trastuzumab emtansine (T-DM1, Kadcyla®), for patients with locally advanced or metastatic HER2-positive (HER2+) breast cancer. This trial is intended to support registration in the U.S. Tucatinib is an oral, …

View Post

Foreign-born women lagging behind US peers in breast cancer screening rates

In In The News by Barbara Jacoby

By: Marty Stempniak From: radiologybusiness.com Breast is the leading cancer killer for Hispanic women in the U.S., and it ranks second among white, black and Asian populations. Incidence of the disease and receipt of crucial mammography screening are often impacted by whether a woman was born in a foreign country, which can snowball into disparities in treatment outcomes. There’s been …

View Post

Metastatic Breast Cancer: What You Should Know

In In The News by Barbara Jacoby

By: Rene Wisely From: uofmhealth.org What does it mean to have metastatic, or stage 4, breast cancer? A Rogel Cancer Center oncologist explains the diagnosis and how it’s treated. After hearing a diagnosis of metastatic breast cancer, a rush of questions emerges. But often, it’s not until long after leaving the doctor’s office. Metastatic means the cancer has spread beyond …

View Post

Patient Selection Key When De-Escalating Radiation in Breast Cancer

In In The News by Barbara Jacoby

By: Danielle Ternyila From: onclive.com Over the past several years, several clinical trials have evaluated the role of radiation in the treatment of patients with breast cancer and whether doses can be reduced. Although de-escalation is possible, patient selection is key, according to Jonathan B. Strauss, MD, MBA. “Selecting the right patients for de-escalation is key. Right now, we are …

View Post

TAILORx High-Risk Group Analysis Adds to Oncotype DX Chemo-Prediction Data

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: genomeweb.com In secondary analysis of data from the TAILORx trial, researchers have added new confirming evidence that patients with high risk scores from Genomic Health’s Oncotype DX appear to benefit significantly from added chemotherapy. Investigators led by the trial’s PI Joseph Sparano shared their findings in JAMA Oncology today and also presented the analysis at the …

View Post

Use of Neoadjuvant Endocrine Therapy Showcases Testing Capabilities in Breast Cancer

In In The News by Barbara Jacoby

By: Darcy Lewis From: onclive.com In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.1 Neoadjuvant endocrine therapy allows clinicians to determine resistance mechanisms to endocrine therapy with or without targeted agents. It also …

View Post

CytoDyn Treats First Patient in Phase 1b/2 Clinical Trial with Leronlimab (PRO 140) for Patients with Treatment-Naïve, Metastatic Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: globenewswire.com CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today the injection of the first patient in a Phase 1b/2 clinical protocol with treatment-naïve metastatic triple-negative breast cancer (mTNBC). The treatment of the first patient in mTNBC with leronlimab …

View Post

Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: prnewswire.com – Significant tumor regression observed with onvansertib in combination with standard-of-care paclitaxel in models of p53-mutated TNBC – Onvansertib preclinical data provides rationale for clinical trial targeting the 80% of TNBC that harbors the p53 mutation – Combination has potential to address critical medical need to provide targeted treatment option to overcome resistance to paclitaxel as single agent …

View Post

Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Health systems in the UK and US could cost-effectively screen all women with breast cancer for risky germline changes in a handful of breast or ovarian cancer genes, according to a new economic modeling analysis, identifying at-risk individuals who could benefit from additional imaging tests and cancer-reducing interventions. “[T]he costs of testing falling … can …